Compare · BSX vs XRAY
BSX vs XRAY
Side-by-side comparison of Boston Scientific Corporation (BSX) and DENTSPLY SIRONA Inc. (XRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and XRAY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 36.0x XRAY ($2.00B).
- XRAY has been more active in the news (16 items in the past 4 weeks vs 12 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- DENTSPLY SIRONA Inc.
- Price
- $48.71+0.31%
- $10.26+2.45%
- Market cap
- $72.16B
- $2.00B
- 1M return
- -
- -6.52%
- 1Y return
- -
- -36.80%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 12
- 16
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest XRAY
- Director Lucier Gregory T received a gift of 38,382 shares, was granted 38,382 shares and gifted 38,382 shares (SEC Form 4)
- Director Zurbay Donald was granted 22,822 shares, increasing direct ownership by 332% to 29,693 units (SEC Form 4)
- Director Vergis Janet S. was granted 22,822 shares, increasing direct ownership by 51% to 67,324 units (SEC Form 4)
- Director Varon Leslie F was granted 22,822 shares, increasing direct ownership by 40% to 80,364 units (SEC Form 4)
- Director Mckeon Brian P was granted 28,887 shares (SEC Form 4)
- Director Mazelsky Jonathan Jay was granted 22,822 shares, increasing direct ownership by 79% to 51,669 units (SEC Form 4)
- Director Hosein Clyde was granted 22,822 shares, increasing direct ownership by 55% to 64,075 units (SEC Form 4)
- Director Holden Betsy D was granted 22,822 shares, increasing direct ownership by 42% to 77,442 units (SEC Form 4)
- Director Gladden Brian T was granted 22,822 shares, increasing direct ownership by 79% to 51,864 units (SEC Form 4)
- Director Forbes James D was granted 28,887 shares, increasing direct ownership by 289% to 38,887 units (SEC Form 4)